WorldHeart RELIANT trial
This article was originally published in The Gray Sheet
Executive Summary
Oakland, Calif.-based company reported Feb. 21 that 20 clinical centers and 29 patients have enrolled in its RELIANT destination therapy trial, which pits the Novacor pulsatile LVAD against Thoratec's HeartMate. WorldHeart anticipates that the additional centers will accelerate patient enrollment for the 390-patient trial. Thoratec's device is the only LVAD approved as a destination therapy for in the U.S. (1"The Gray Sheet" March 28, 2005, p. 17)...